Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane

Bibliographic Details
Main Authors:	Lv, Fangfang, Cao, Jun, Liu, Zhebin, Wang, Zhonghua, Zhang, Jian, Zhang, Sheng, Wang, Leiping, Zhao, Xinmin, Shao, Zhimin, Wang, Biyun, Hu, Xichun
Format:	Online
Language:	English
Published:	Public Library of Science 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359133/

Similar Items

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
by: Li, Ting, et al.
Published: (2015)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
by: Lee, Yu Rim, et al.
Published: (2011)

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
by: Fukuda, Takayo, et al.
Published: (2015)

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis
by: Jiang, Yiwei, et al.
Published: (2012)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
by: Wang, Leiping, et al.
Published: (2011)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
by: Kim, Jung Sun, et al.
Published: (2014)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
by: Tanabe, Masahiko
Published: (2016)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
by: Saji, Shigehira
Published: (2013)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.
by: Pedro Veronese, et al.

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
by: Jia Jin, et al.
Published: (2018-04-01)

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
by: Liu, Rujiao, et al.
Published: (2016)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
by: li, Meiying, et al.
Published: (2015)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
by: Zheng, Yi, et al.
Published: (2015)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
by: Dai, Kun, et al.
Published: (2015)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
by: Zhang, Jian, et al.
Published: (2015)

Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials
by: Zheng, Ruinian, et al.
Published: (2015)

A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials
by: Xu, Liang, et al.
Published: (2016)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
by: Zhao, Xinmin, et al.
Published: (2011)

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
by: Kaufman, Peter A., et al.
Published: (2015)

Pseudomonas aeruginosa mannose-sensitive hemagglutinin inhibits proliferation and invasion via the PTEN/AKT pathway in HeLa cells
by: Yin, Tie-qiu, et al.
Published: (2016)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
by: Sun, Si, et al.
Published: (2014)

Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy
by: Lee, Anbok, et al.
Published: (2011)

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
by: Pajares, Bella, et al.
Published: (2013)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
by: Aomatsu, Naoki, et al.
Published: (2014)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
by: Saji, Shigehira
Published: (2013)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
by: Pourali, Leila, et al.
Published: (2013)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
by: Susini, Tommaso, et al.
Published: (2014)

PRP4K is a HER2-regulated modifier of taxane sensitivity
by: Corkery, Dale P, et al.
Published: (2015)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
by: Hansen, Ryan N, et al.
Published: (2014)

Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer
by: Montemurro, Filippo, et al.
Published: (2010)

Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines
by: ZHU, YI-PING, et al.
Published: (2013)

Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans
by: Lin, Shih-Chang, et al.
Published: (2013)

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
by: Fernández-Cuesta, Lynnette, et al.
Published: (2012)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
by: Zhang, Pin, et al.
Published: (2016)

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
by: Lee, Hee Jin, et al.
Published: (2015)

Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer – clinical evaluation of sensor-controlled scalp cooling
by: Friedrichs, Kay, et al.
Published: (2014)

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer
by: Pérez-Fidalgo, J. A., et al.
Published: (2014)

P-gp and taxanes
by: Hendrikx, Jeroen J.M.A., et al.
Published: (2014)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
by: Fabi, Alessandra, et al.
Published: (2015)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
by: Park, Y H, et al.
Published: (2014)